Molecular models for hydralazine‐related systemic lupus erythematosus
Hydralazine is the prototypic drug that induces lupus. It does so in 10-20% of patients treated on a long-term basis. Patients who are slow acetylators of hydralazine more commonly develop antinuclear antibodies and drug-related SLE. Therefore, the study of possible molecular mechanisms in hydralazi...
Gespeichert in:
| Veröffentlicht in: | Arthritis and rheumatism 1981-08, Vol.24 (8), p.1082-1085 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1085 |
|---|---|
| container_issue | 8 |
| container_start_page | 1082 |
| container_title | Arthritis and rheumatism |
| container_volume | 24 |
| creator | Dubroff, Lewis Reid, Robert Papalian, Michael |
| description | Hydralazine is the prototypic drug that induces lupus. It does so in 10-20% of patients treated on a long-term basis. Patients who are slow acetylators of hydralazine more commonly develop antinuclear antibodies and drug-related SLE. Therefore, the study of possible molecular mechanisms in hydralazine-related SLE may be important in understanding various connective tissue diseases. |
| doi_str_mv | 10.1002/art.1780240817 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_15456226</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>15456226</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3717-597f00fddf597d40af64b983f195ad97d0c838c5c66646e2ebbbeb3173ebad463</originalsourceid><addsrcrecordid>eNqFkLtOwzAUhi0EKuWysiFlYkux40uSsaqgIBUhoTJbjn2sBjl1sROhMPEIPCNPQqpWwMZ0bv_5hg-hC4InBOPsWoV2QvICZwwXJD9AY8KzMsWEkkM0xhizlPKSHKOTGF-GMaOcjtBIlDnjXIzR_ME70J1TIWm8ARcT60Oy6k1QTr3Xa_j6-AzgVAsmiX1soal14rpNFxMIfbuCRrU-dvEMHVnlIpzv6yl6vr1Zzu7SxeP8fjZdpJrmJE95mVuMrTF26AzDygpWlQW1pOTKDCusC1poroUQTEAGVVVBRUlOoVKGCXqKrnbcTfCvHcRWNnXU4Jxag--iJJxxkWXb4GQX1MHHGMDKTagbFXpJsNyak4M5-WtueLjck7uqAfMT36sa7uXu_lY76P-hyenT8g_7G5CpfMw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>15456226</pqid></control><display><type>article</type><title>Molecular models for hydralazine‐related systemic lupus erythematosus</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Alma/SFX Local Collection</source><creator>Dubroff, Lewis ; Reid, Robert ; Papalian, Michael</creator><creatorcontrib>Dubroff, Lewis ; Reid, Robert ; Papalian, Michael</creatorcontrib><description>Hydralazine is the prototypic drug that induces lupus. It does so in 10-20% of patients treated on a long-term basis. Patients who are slow acetylators of hydralazine more commonly develop antinuclear antibodies and drug-related SLE. Therefore, the study of possible molecular mechanisms in hydralazine-related SLE may be important in understanding various connective tissue diseases.</description><identifier>ISSN: 0004-3591</identifier><identifier>EISSN: 1529-0131</identifier><identifier>DOI: 10.1002/art.1780240817</identifier><identifier>PMID: 6974556</identifier><language>eng</language><publisher>New York: John Wiley & Sons, Inc</publisher><subject>Antibodies, Antinuclear ; Chromatin ; DNA - immunology ; DNA - metabolism ; Histones - immunology ; Humans ; Hydralazine - adverse effects ; Lupus Erythematosus, Systemic - chemically induced ; Models, Molecular ; Models, Structural ; Mutagens ; Nucleosomes ; Thymidine - metabolism</subject><ispartof>Arthritis and rheumatism, 1981-08, Vol.24 (8), p.1082-1085</ispartof><rights>Copyright © 1981 American College of Rheumatology</rights><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3717-597f00fddf597d40af64b983f195ad97d0c838c5c66646e2ebbbeb3173ebad463</citedby><cites>FETCH-LOGICAL-c3717-597f00fddf597d40af64b983f195ad97d0c838c5c66646e2ebbbeb3173ebad463</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fart.1780240817$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fart.1780240817$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,777,781,1412,27905,27906,45555,45556</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/6974556$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dubroff, Lewis</creatorcontrib><creatorcontrib>Reid, Robert</creatorcontrib><creatorcontrib>Papalian, Michael</creatorcontrib><title>Molecular models for hydralazine‐related systemic lupus erythematosus</title><title>Arthritis and rheumatism</title><addtitle>Arthritis Rheum</addtitle><description>Hydralazine is the prototypic drug that induces lupus. It does so in 10-20% of patients treated on a long-term basis. Patients who are slow acetylators of hydralazine more commonly develop antinuclear antibodies and drug-related SLE. Therefore, the study of possible molecular mechanisms in hydralazine-related SLE may be important in understanding various connective tissue diseases.</description><subject>Antibodies, Antinuclear</subject><subject>Chromatin</subject><subject>DNA - immunology</subject><subject>DNA - metabolism</subject><subject>Histones - immunology</subject><subject>Humans</subject><subject>Hydralazine - adverse effects</subject><subject>Lupus Erythematosus, Systemic - chemically induced</subject><subject>Models, Molecular</subject><subject>Models, Structural</subject><subject>Mutagens</subject><subject>Nucleosomes</subject><subject>Thymidine - metabolism</subject><issn>0004-3591</issn><issn>1529-0131</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1981</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkLtOwzAUhi0EKuWysiFlYkux40uSsaqgIBUhoTJbjn2sBjl1sROhMPEIPCNPQqpWwMZ0bv_5hg-hC4InBOPsWoV2QvICZwwXJD9AY8KzMsWEkkM0xhizlPKSHKOTGF-GMaOcjtBIlDnjXIzR_ME70J1TIWm8ARcT60Oy6k1QTr3Xa_j6-AzgVAsmiX1soal14rpNFxMIfbuCRrU-dvEMHVnlIpzv6yl6vr1Zzu7SxeP8fjZdpJrmJE95mVuMrTF26AzDygpWlQW1pOTKDCusC1poroUQTEAGVVVBRUlOoVKGCXqKrnbcTfCvHcRWNnXU4Jxag--iJJxxkWXb4GQX1MHHGMDKTagbFXpJsNyak4M5-WtueLjck7uqAfMT36sa7uXu_lY76P-hyenT8g_7G5CpfMw</recordid><startdate>198108</startdate><enddate>198108</enddate><creator>Dubroff, Lewis</creator><creator>Reid, Robert</creator><creator>Papalian, Michael</creator><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TM</scope><scope>7U7</scope><scope>C1K</scope><scope>H94</scope></search><sort><creationdate>198108</creationdate><title>Molecular models for hydralazine‐related systemic lupus erythematosus</title><author>Dubroff, Lewis ; Reid, Robert ; Papalian, Michael</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3717-597f00fddf597d40af64b983f195ad97d0c838c5c66646e2ebbbeb3173ebad463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1981</creationdate><topic>Antibodies, Antinuclear</topic><topic>Chromatin</topic><topic>DNA - immunology</topic><topic>DNA - metabolism</topic><topic>Histones - immunology</topic><topic>Humans</topic><topic>Hydralazine - adverse effects</topic><topic>Lupus Erythematosus, Systemic - chemically induced</topic><topic>Models, Molecular</topic><topic>Models, Structural</topic><topic>Mutagens</topic><topic>Nucleosomes</topic><topic>Thymidine - metabolism</topic><toplevel>online_resources</toplevel><creatorcontrib>Dubroff, Lewis</creatorcontrib><creatorcontrib>Reid, Robert</creatorcontrib><creatorcontrib>Papalian, Michael</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Arthritis and rheumatism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dubroff, Lewis</au><au>Reid, Robert</au><au>Papalian, Michael</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Molecular models for hydralazine‐related systemic lupus erythematosus</atitle><jtitle>Arthritis and rheumatism</jtitle><addtitle>Arthritis Rheum</addtitle><date>1981-08</date><risdate>1981</risdate><volume>24</volume><issue>8</issue><spage>1082</spage><epage>1085</epage><pages>1082-1085</pages><issn>0004-3591</issn><eissn>1529-0131</eissn><abstract>Hydralazine is the prototypic drug that induces lupus. It does so in 10-20% of patients treated on a long-term basis. Patients who are slow acetylators of hydralazine more commonly develop antinuclear antibodies and drug-related SLE. Therefore, the study of possible molecular mechanisms in hydralazine-related SLE may be important in understanding various connective tissue diseases.</abstract><cop>New York</cop><pub>John Wiley & Sons, Inc</pub><pmid>6974556</pmid><doi>10.1002/art.1780240817</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0004-3591 |
| ispartof | Arthritis and rheumatism, 1981-08, Vol.24 (8), p.1082-1085 |
| issn | 0004-3591 1529-0131 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_15456226 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Alma/SFX Local Collection |
| subjects | Antibodies, Antinuclear Chromatin DNA - immunology DNA - metabolism Histones - immunology Humans Hydralazine - adverse effects Lupus Erythematosus, Systemic - chemically induced Models, Molecular Models, Structural Mutagens Nucleosomes Thymidine - metabolism |
| title | Molecular models for hydralazine‐related systemic lupus erythematosus |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T03%3A31%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Molecular%20models%20for%20hydralazine%E2%80%90related%20systemic%20lupus%20erythematosus&rft.jtitle=Arthritis%20and%20rheumatism&rft.au=Dubroff,%20Lewis&rft.date=1981-08&rft.volume=24&rft.issue=8&rft.spage=1082&rft.epage=1085&rft.pages=1082-1085&rft.issn=0004-3591&rft.eissn=1529-0131&rft_id=info:doi/10.1002/art.1780240817&rft_dat=%3Cproquest_cross%3E15456226%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=15456226&rft_id=info:pmid/6974556&rfr_iscdi=true |